Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Fexofenadine hydrochloride (Allegra) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine. Fexofenadine, like other second and third-generation antihistamines, does not readily pass through the blood-brain barrier, and so causes less drowsiness than first-generation histamine-receptor antagonists. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # Smith SM, Gums JG: Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19545214 # Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19539095 # Markham A, Wagstaff AJ: Fexofenadine. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9506246 # Golightly LK, Greos LS: Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs. 2005;65(3):341-84. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15669879 # Molimard M, Diquet B, Benedetti MS: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15312146 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For management of Seasonal allergic rhinitis (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Like other H1-blockers, Fexofenadine competes with free histamine for binding at H1-receptors in the GI tract, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Fexofenadine exhibits no anticholinergic, antidopaminergic, alpha1-adrenergic or beta-adrenergic-receptor blocking effects. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...y/drugbank/patent
| |
http://linked.open.../drugbank/synonym
| - Fexofenadine (en)
- Carboxyterfenadine (en)
- Terfenadine acid metabolite (en)
- Terfenadine carboxylate (en)
- Terfenadine-COOH (en)
- 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid (en)
|
http://linked.open...drugbank/toxicity
| - Side effects include dizziness, drowsiness, and dry mouth. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Take without regard to meals. (en)
- Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly decrease serum levels of this product. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...nk/proteinBinding
| |
http://linked.open...ynthesisReference
| - Federico Milla, "Processes for the production of fexofenadine." U.S. Patent US20030166682, issued September 04, 2003. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |